{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T19:09:43Z","timestamp":1788808183998,"version":"build-2803163510"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T00:00:00Z","timestamp":1760918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T00:00:00Z","timestamp":1760918400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100005977","name":"Kaiser Permanente","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005977","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Prev Sci"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Hospitalization and death following COVID-19 infection continue to pose a major public health concern and place strain on health system resources. Outpatient antiviral medication can reduce the risk of COVID-19 hospitalization and death for those at risk of poor outcomes, but identifying high-risk populations who may benefit most from treatment is challenging. The objective of this study was to develop and validate a prediction model for the composite outcome of hospitalization or death in the 14\u00a0days following COVID-19 infection. Our sample included 67,530 COVID-19 infections documented in outpatient care and occurring between April 1, 2020, and November 1, 2022, for 64,529 Kaiser Permanente Washington patients who did not receive outpatient antiviral treatment; 1378 (2.0%) of these infections resulted in hospitalization or death. Our prediction model, estimated using logistic regression with LASSO variable selection and ridge penalization, included 19 risk factors and showed high performance, including an area under the curve of 0.825 (95% confidence interval 0.813\u20130.836). Among the 10% of infections with the highest risk predictions, the true positive rate was 48% (46\u201351%) and the positive predictive value was 9.9% (9.2\u201310.6%). Supplemental analyses confirmed strong model performance across racial and ethnic subgroups and over time. We also present our process for selecting a risk threshold above which to recommend antiviral treatment and discuss considerations for prospective clinical implementation. This project demonstrates that machine learning tools can be used by health systems to deliver timely, targeted secondary prevention to reduce the risk of serious illness or death.<\/jats:p>","DOI":"10.1007\/s11121-025-01844-5","type":"journal-article","created":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T02:21:01Z","timestamp":1760926861000},"page":"1023-1035","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Development and Validation of an Electronic Health Record-Derived Prediction Model for Preventing COVID-19 Hospitalization and Death"],"prefix":"10.1007","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1708-4880","authenticated-orcid":false,"given":"R Yates","family":"Coley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Hays","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roy E.","family":"Pardee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon","family":"Fuller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristine","family":"Rogers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire L.","family":"Allen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David E.","family":"Arterburn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert K.","family":"Frazier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J.","family":"Kent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophia","family":"Mun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tolani","family":"Mwatha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Thottingal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily O.","family":"Westbrook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,20]]},"reference":[{"issue":"10","key":"1844_CR1","doi-asserted-by":"publisher","first-page":"e2130479","DOI":"10.1001\/jamanetworkopen.2021.30479","volume":"4","author":"AM Acosta","year":"2021","unstructured":"Acosta, A. M., Garg, S., Pham, H., Whitaker, M., Anglin, O., O\u2019Halloran, A., et al. (2021). Racial and ethnic disparities in rates of COVID-19\u2013associated hospitalization, intensive care unit admission, and in-hospital death in the United States From March 2020 to February 2021. JAMA Network Open, 4(10), e2130479\u2013e2130479.","journal-title":"JAMA Network Open"},{"key":"1844_CR2","doi-asserted-by":"crossref","unstructured":"Ahmad FB. Mortality in the United States \u2014 Provisional Data, 2023. MMWR Morb Mortal Wkly Rep [Internet]. 2024 [cited 2025 Jun 27];73. Available from: https:\/\/www.cdc.gov\/mmwr\/volumes\/73\/wr\/mm7331a1.htm","DOI":"10.15585\/mmwr.mm7331a1"},{"issue":"6","key":"1844_CR3","doi-asserted-by":"publisher","first-page":"807","DOI":"10.7326\/M22-3565","volume":"176","author":"KL Bajema","year":"2023","unstructured":"Bajema, K. L., Berry, K., Streja, E., Rajeevan, N., Li, Y., Mutalik, P., et al. (2023). Effectiveness of COVID-19 treatment with nirmatrelvir-ritonavir or molnupiravir among U.S. Veterans: Target trial emulation studies with one-month and six-month outcomes. Annals of Internal Medicine, 176(6), 807\u201316.","journal-title":"Annals of Internal Medicine"},{"issue":"6","key":"1844_CR4","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1377\/hlthaff.2020.00426","volume":"39","author":"SM Bartsch","year":"2020","unstructured":"Bartsch, S. M., Ferguson, M. C., McKinnell, J. A., O\u2019Shea, K. J., Wedlock, P. T., Siegmund, S. S., et al. (2020). The potential health care costs and resource use associated with COVID-19 in the United States. Health Affairs Proj Hope, 39(6), 927\u2013935.","journal-title":"Health Affairs Proj Hope"},{"issue":"43","key":"1844_CR5","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.15585\/mmwr.mm7143a2","volume":"71","author":"TK Boehmer","year":"2022","unstructured":"Boehmer, T. K., Koumans, E. H., Skillen, E. L., Kappelman, M. D., Carton, T. W., Patel, A., et al. (2022). Racial and ethnic disparities in outpatient treatment of COVID-19 - United States, January-July 2022. MMWR Morbidity and Mortality Weekly Report, 71(43), 1359\u20131365.","journal-title":"MMWR Morbidity and Mortality Weekly Report"},{"key":"1844_CR6","unstructured":"CDC. CDC Releases New In-Season Estimates for COVID-19 and RSV [Internet]. National Center for Immunization and Respiratory Diseases. 2025 [cited 2025 Jun 27]. Available from: https:\/\/www.cdc.gov\/ncird\/whats-new\/cdc-releases-new-in-season-estimates-for-covid-19-and-rsv.html"},{"key":"1844_CR7","unstructured":"CDC. COVID Data Tracker [Internet]. Centers for Disease Control and Prevention. (2020) [cited 2025 Jun 27]. Available from: https:\/\/covid.cdc.gov\/covid-data-tracker"},{"key":"1844_CR8","unstructured":"CDC. Provisional COVID-19 Mortality Surveillance [Internet]. [cited 2025 Jun 27]. Available from: https:\/\/www.cdc.gov\/nchs\/nvss\/vsrr\/covid19\/"},{"key":"1844_CR9","unstructured":"CDC. Weekly US Influenza Surveillance Report: Key Updates for Week 17, ending April 26, 2025 [Internet]. FluView. 2025 [cited 2025 Jun 27]. Available from: https:\/\/www.cdc.gov\/fluview\/surveillance\/2025-week-17.html"},{"issue":"3","key":"1844_CR10","doi-asserted-by":"publisher","first-page":"e246","DOI":"10.1097\/MJT.0000000000001744","volume":"31","author":"AS Cha-Silva","year":"2024","unstructured":"Cha-Silva, A. S., Gavaghan, M. B., Bergroth, T., Alexander-Parrish, R., Yang, J., Draica, F., et al. (2024). Effectiveness of nirmatrelvir-ritonavir for the prevention of COVID-19\u2013related hospitalization and mortality: A systematic literature review. American Journal of Therapeutics, 31(3), e246.","journal-title":"American Journal of Therapeutics"},{"issue":"1","key":"1844_CR11","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s12874-023-01844-5","volume":"23","author":"RY Coley","year":"2023","unstructured":"Coley, R. Y., Liao, Q., Simon, N., & Shortreed, S. M. (2023). Empirical evaluation of internal validation methods for prediction in large-scale clinical data with rare-event outcomes: A case study in suicide risk prediction. BMC Medical Research Methodology, 23(1), 33.","journal-title":"BMC Medical Research Methodology"},{"issue":"12","key":"1844_CR12","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.1093\/cid\/ciab154","volume":"73","author":"CL Dai","year":"2021","unstructured":"Dai, C. L., Kornilov, S. A., Roper, R. T., Cohen-Cline, H., Jade, K., Smith, B., et al. (2021). Characteristics and factors associated with coronavirus disease 2019 infection, hospitalization, and mortality across race and ethnicity. Clinical Infectious Diseases, 73(12), 2193\u20132204.","journal-title":"Clinical Infectious Diseases"},{"issue":"378","key":"1844_CR13","doi-asserted-by":"publisher","first-page":"e069881","DOI":"10.1136\/bmj-2021-069881","volume":"12","author":"VMT de Jong","year":"2022","unstructured":"de Jong, V. M. T., Rousset, R. Z., Antonio-Villa, N. E., Buenen, A. G., Van Calster, B., Bello-Chavolla, O. Y., et al. (2022). Clinical prediction models for mortality in patients with covid-19: External validation and individual participant data meta-analysis. BMJ, 12(378), e069881.","journal-title":"BMJ"},{"key":"1844_CR14","unstructured":"FDA. (2024). Center for Drug Evaluation and Research. FDA revises letter of authorization for the emergency use authorization for Paxlovid. FDA [Internet]. [cited 2025 Jun 27]; Available from: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-revises-letter-authorization-emergency-use-authorization-paxlovid"},{"issue":"46","key":"1844_CR15","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.15585\/mmwr.mm7046a5","volume":"70","author":"G French","year":"2021","unstructured":"French, G., Hulse, M., Nguyen, D., Sobotka, K., Webster, K., Corman, J., et al. (2021). Impact of hospital strain on excess deaths during the COVID-19 pandemic - United States, July 2020-July 2021. MMWR Morbidity and Mortality Weekly Report, 70(46), 1613\u20131616.","journal-title":"MMWR Morbidity and Mortality Weekly Report"},{"issue":"7","key":"1844_CR16","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1016\/j.jclinepi.2010.10.004","volume":"64","author":"JJ Gagne","year":"2011","unstructured":"Gagne, J. J., Glynn, R. J., Avorn, J., Levin, R., & Schneeweiss, S. (2011). A combined comorbidity score predicted mortality in elderly patients better than existing scores. Journal of Clinical Epidemiology, 64(7), 749\u2013759.","journal-title":"Journal of Clinical Epidemiology"},{"key":"1844_CR17","unstructured":"GoodRx (2025). Paxlovid Prices Coupons & Savings Tips - GoodRx [Internet]. [cited 2025 Jun 27]. Available from: https:\/\/www.goodrx.com\/paxlovid"},{"issue":"9","key":"1844_CR18","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0239536","volume":"15","author":"K Hajifathalian","year":"2020","unstructured":"Hajifathalian, K., Sharaiha, R. Z., Kumar, S., Krisko, T., Skaf, D., Ang, B., et al. (2020). Development and external validation of a prediction risk model for short-term mortality among hospitalized U.S. COVID-19 patients: A proposal for the COVID-AID risk tool. PLoS ONE, 15(9), Article e0239536.","journal-title":"PLoS ONE"},{"issue":"15","key":"1844_CR19","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1056\/NEJMoa2118542","volume":"386","author":"J Hammond","year":"2022","unstructured":"Hammond, J., Leister-Tebbe, H., Gardner, A., Abreu, P., Bao, W., Wisemandle, W., et al. (2022). Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19. New England Journal of Medicine, 386(15), 1397\u20131408.","journal-title":"New England Journal of Medicine"},{"issue":"381","key":"1844_CR20","doi-asserted-by":"publisher","first-page":"e072976","DOI":"10.1136\/bmj-2022-072976","volume":"21","author":"J Hippisley-Cox","year":"2023","unstructured":"Hippisley-Cox, J., Khunti, K., Sheikh, A., Nguyen-Van-Tam, J. S., & Coupland, C. A. C. (2023). Risk prediction of covid-19 related death or hospital admission in adults testing positive for SARS-CoV-2 infection during the omicron wave in England (QCOVID4): Cohort study. BMJ, 21(381), e072976.","journal-title":"BMJ"},{"issue":"13","key":"1844_CR21","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1056\/NEJMoa2309003","volume":"390","author":"H Jennifer","year":"2024","unstructured":"Hammond, J., Fountaine, R. J., Yunis, C., Fleishaker, D., Almas, M., Bao, W.H., et al. (2024). Nirmatrelvir for vaccinated or unvaccinated adult outpatients with Covid-19. New England Journal of Medicine, 390(13), 1186\u201395.","journal-title":"New England Journal of Medicine"},{"issue":"6","key":"1844_CR22","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1093\/cid\/ciad266","volume":"77","author":"JY Ko","year":"2023","unstructured":"Ko, J. Y., Pham, H., Anglin, O., Chai, S. J., Alden, N. B., Meek, J., et al. (2023). Vaccination status and trends in adult coronavirus disease 2019-associated hospitalizations by race and ethnicity: March 2020-August 2022. Clinical Infectious Diseases, 77(6), 827\u2013838.","journal-title":"Clinical Infectious Diseases"},{"issue":"6","key":"1844_CR23","doi-asserted-by":"publisher","DOI":"10.1111\/1475-6773.14382","volume":"59","author":"JR Ledesma","year":"2024","unstructured":"Ledesma, J. R., Chrysanthopoulou, S. A., Lurie, M. N., Nuzzo, J. B., & Papanicolas, I. (2024). Health system resilience during the COVID-19 pandemic: A comparative analysis of disruptions in care from 32 countries. Health Services Research, 59(6), Article e14382.","journal-title":"Health Services Research"},{"issue":"3","key":"1844_CR24","doi-asserted-by":"publisher","first-page":"362","DOI":"10.7326\/M20-6306","volume":"174","author":"K Mackey","year":"2021","unstructured":"Mackey, K., Ayers, C. K., Kondo, K. K., Saha, S., Advani, S. M., Young, S., et al. (2021). Racial and ethnic disparities in COVID-19-related infections, hospitalizations, and deaths: A systematic review. Annals of Internal Medicine, 174(3), 362\u2013373.","journal-title":"Annals of Internal Medicine"},{"issue":"10","key":"1844_CR25","doi-asserted-by":"publisher","first-page":"e1001744","DOI":"10.1371\/journal.pmed.1001744","volume":"11","author":"KGM Moons","year":"2014","unstructured":"Moons, K. G. M., de Groot, J. A. H., Bouwmeester, W., Vergouwe, Y., Mallett, S., Altman, D. G., et al. (2014). Critical appraisal and data extraction for systematic reviews of prediction modelling studies: The CHARMS checklist. PLoS Medicine, 11(10), e1001744.","journal-title":"PLoS Medicine"},{"issue":"54","key":"1844_CR26","doi-asserted-by":"publisher","first-page":"126966","DOI":"10.1016\/j.vaccine.2025.126966","volume":"30","author":"M Moore","year":"2025","unstructured":"Moore, M., Anderson, L., Schiffer, J. T., Matrajt, L., & Dimitrov, D. (2025). Durability of COVID-19 vaccine and infection induced immunity: A systematic review and meta-regression analysis. Vaccine, 30(54), 126966.","journal-title":"Vaccine"},{"key":"1844_CR27","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.ijsu.2020.04.001","volume":"77","author":"M Nicola","year":"2020","unstructured":"Nicola, M., O\u2019Neill, N., Sohrabi, C., Khan, M., Agha, M., & Agha, R. (2020). Evidence based management guideline for the COVID-19 pandemic - Review article. International Journal of Surgery (London, England), 77, 206\u2013216.","journal-title":"International Journal of Surgery (London, England)"},{"key":"1844_CR28","unstructured":"Pfizer. (2025). Pfizer\u2019s PAXLOVIDTM Receives FDA Approval for Adult Patients at High Risk of Progression to Severe COVID-19. Pfizer [Internet]. [cited 2025 Jun 27]. Available from: https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/pfizers-paxlovidtm-receives-fda-approval-adult-patients"},{"issue":"1","key":"1844_CR29","doi-asserted-by":"publisher","DOI":"10.13063\/2327-9214.1049","volume":"2","author":"TR Ross","year":"2014","unstructured":"Ross, T. R., Ng, D., Brown, J. S., Pardee, R., Hornbrook, M. C., Hart, G., et al. (2014). The HMO research network virtual data warehouse: A public data model to support collaboration. EgemS (Generating Evidence & Methods to Improve Patient Outcomes), 2(1), Article 1049.","journal-title":"EgemS (Generating Evidence & Methods to Improve Patient Outcomes)"},{"issue":"3","key":"1844_CR30","first-page":"100228","volume":"3","author":"A Saelmans","year":"2025","unstructured":"Saelmans, A., Seinen, T., Pera, V., Markus, A. F., Fridgeirsson, E., John, L. H., et al. (2025). Implementation and updating of clinical prediction models: A systematic review. Mayo Clinic Proceedings: Digital Health, 3(3), 100228.","journal-title":"Mayo Clinic Proceedings: Digital Health"},{"key":"1844_CR31","doi-asserted-by":"crossref","unstructured":"Shah MM. (2022). Paxlovid Associated with Decreased Hospitalization Rate Among Adults with COVID-19 \u2014 United States, April\u2013September 2022. MMWR Morb Mortal Wkly Rep [Internet]. 2022 [cited 2025 Jun 27];71. Available from: https:\/\/www.cdc.gov\/mmwr\/volumes\/71\/wr\/mm7148e2.htm","DOI":"10.15585\/mmwr.mm7148e2"},{"issue":"1","key":"1844_CR32","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/s40615-021-01205-2","volume":"10","author":"SM Shortreed","year":"2023","unstructured":"Shortreed, S. M., Gray, R., Akosile, M. A., Walker, R. L., Fuller, S., Temposky, L., et al. (2023). Increased COVID-19 infection risk drives racial and ethnic disparities in severe COVID-19 outcomes. Journal of Racial and Ethnic Health Disparities, 10(1), 149\u2013159.","journal-title":"Journal of Racial and Ethnic Health Disparities"},{"issue":"5","key":"1844_CR33","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1093\/cid\/ciad696","volume":"78","author":"SE Smith-Jeffcoat","year":"2024","unstructured":"Smith-Jeffcoat, S. E., Biddle, J. E., Talbot, H. K., Morrissey, K. G., Stockwell, M. S., Maldonado, Y., et al. (2024). Symptoms, viral loads, and rebound among COVID-19 outpatients treated with Nirmatrelvir\/ritonavir compared with propensity score-matched untreated individuals. Clinical Infectious Diseases, 78(5), 1175\u20131184.","journal-title":"Clinical Infectious Diseases"},{"key":"1844_CR34","doi-asserted-by":"crossref","unstructured":"Steyerberg, E. W. (2019). Clinical prediction models: A practical approach to development, validation, and updating (2nd ed.). Springer.","DOI":"10.1007\/978-3-030-16399-0"},{"issue":"8","key":"1844_CR35","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1016\/S0895-4356(01)00341-9","volume":"54","author":"EW Steyerberg","year":"2001","unstructured":"Steyerberg, E. W., Harrell, F. E., Borsboom, G. J. J. M., Eijkemans, M. J. C., Vergouwe, Y., & Habbema, J. D. F. (2001). Internal validation of predictive models: Efficiency of some procedures for logistic regression analysis. Journal of Clinical Epidemiology, 54(8), 774\u2013781.","journal-title":"Journal of Clinical Epidemiology"},{"key":"1844_CR36","unstructured":"The NNT. (2025) Paxlovid for Nonhospitalized Patients with COVID-19 . TheNNT [Internet]. [cited 2025 Jun 27]. Available from: https:\/\/thennt.com\/nnt\/paxlovid-for-nonhospitalized-patients-with-covid-19\/"},{"issue":"1","key":"1844_CR37","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1111\/j.2517-6161.1996.tb02080.x","volume":"58","author":"R Tibshirani","year":"1996","unstructured":"Tibshirani, R. (1996). Regression shrinkage and selection via the lasso. Journal of the Royal Statistical Society Series b: Statistical Methodology, 58(1), 267\u2013288.","journal-title":"Journal of the Royal Statistical Society Series b: Statistical Methodology"},{"key":"1844_CR38","unstructured":"WHO. (2024). COVID-19 epidemiological update \u2013 24 December 2024 [Internet]. [cited 2025 Jun 27]. Available from: https:\/\/www.who.int\/publications\/m\/item\/covid-19-epidemiological-update---24-december-2024"},{"issue":"8","key":"1844_CR39","doi-asserted-by":"publisher","DOI":"10.1002\/pds.5869","volume":"33","author":"X Xiao","year":"2024","unstructured":"Xiao, X., Alexander, G. C., & Mehta, H. B. (2024). Nirmatrelvir\/Ritonavir (Paxlovid) use among individuals at risk of severe COVID-19: An analysis of the National COVID Cohort Collaborative (N3C). Pharmacoepidemiology and Drug Safety, 33(8), Article e5869.","journal-title":"Pharmacoepidemiology and Drug Safety"},{"issue":"1","key":"1844_CR40","doi-asserted-by":"publisher","first-page":"16913","DOI":"10.1038\/s41598-022-20724-4","volume":"12","author":"Y Xu","year":"2022","unstructured":"Xu, Y., Trivedi, A., Becker, N., Blazes, M., Ferres, J. L., Lee, A., et al. (2022). Machine learning-based derivation and external validation of a tool to predict death and development of organ failure in hospitalized patients with COVID-19. Science and Reports, 12(1), 16913.","journal-title":"Science and Reports"}],"container-title":["Prevention Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11121-025-01844-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11121-025-01844-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11121-025-01844-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T19:03:14Z","timestamp":1788807794000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11121-025-01844-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,20]]},"references-count":40,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["1844"],"URL":"https:\/\/doi.org\/10.1007\/s11121-025-01844-5","relation":{},"ISSN":["1389-4986","1573-6695"],"issn-type":[{"value":"1389-4986","type":"print"},{"value":"1573-6695","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,20]]},"assertion":[{"value":"10 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The Kaiser Permanente Washington Health Research Institute IRB determined this quality improvement initiative was not research (IRB#1972759).","order":1,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable as the project received a determination of not human subject research.","order":2,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None of the authors have any conflicts of interest. R. Yates Coley holds a secondary affiliation with the University of Washington Department of Biostatistics. David E. Arterburn holds a secondary affiliation with the University of Washington Department of Medicine. Daniel J. Kent holds a secondary affiliation with the University of Washington School of Pharmacy.","order":3,"name":"Ethics","label":"Conflicts of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}